TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
1.1 OVERVIEW
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
2.5 ASSUMPTIONS & LIMITATIONS
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.4 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.6.1 BOTTOM-UP APPROACH
3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION
4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 INCREASING INCIDENTS OF FUNGAL INFECTIONS
4.2.2 INCREASING PREVALENCE OF IMMUNOLOGICAL DISEASES
4.2.3 AVAILABILITY OF A WIDE RANGE OF PRODUCTS
4.3 RESTRAINTS
4.3.1 SIDE-EFFECTS OF TREATMENT
4.4 OPPORTUNITIES
4.4.1 DEVELOPMENT OF NEW DRUGS
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 R&D & DESIGNING
5.1.2 MANUFACTURING
5.1.3 DISTRIBUTION & SALES
5.1.4 POST-SALES MONITORING
5.2 PORTER'S FIVE FORCES MODEL
5.2.1 THREAT OF NEW ENTRANTS
5.2.2 BARGAINING POWER OF SUPPLIERS
5.2.3 THREAT OF SUBSTITUTES
5.2.4 BARGAINING POWER OF BUYERS
5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON THE GLOBAL ANTI-FUNGAL TREATMENT MARKET
5.3.1 IMPACT ON MAKET GROWTH
5.3.2 IMPACT ON SUPPLY CHAIN
5.3.3 IMPACT ON DIAGNOSTICS AND TESTING
5.3.4 CHANGES IN HEALTHCARE PRIORITIES
5.3.5 IMPACT ON CLINICAL TRIALS
6 GLOBAL ANTIFUNGAL TREATMENT MARKET, BY DRUG CLASS
6.1 OVERVIEW
6.2 AZOLES
6.3 ECHINOCANDINS
6.4 POLYENES
6.5 ALLYLAMINES
6.6 PYRIMIDINES
6.7 OTHERS
7 GLOBAL ANTIFUNGAL TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
7.1 OVERVIEW
7.2 ORAL
7.3 TOPICAL
7.4 PARENTERAL
8 GLOBAL ANTIFUNGAL TREATMENT MARKET, BY INDICATION
8.1 OVERVIEW
8.2 DERMATOPHYTOSIS
8.3 ASPERGILLOSIS
8.4 CANDIDIASIS.
8.5 INVASIVE CANDIDIASIS.
8.6 VULVOVAGINAL CANDIDIASIS
8.7 MOUTH/THROAT/ESOPHAGEAL CANDIDIASIS
8.8 OTHERS
9 GLOBAL ANTIFUNGAL TREATMENT MARKET, BY PATHOGENS
9.1 OVERVIEW
9.2 CANDIDA
9.3 ASPERGILLUS
9.4 CRYPTOCOCCUS
9.5 COCCIDIOIDES IMMITIS.
9.6 ZYGOMYCETES
9.7 TRICHOPHYTON
9.8 OTHERS
10 GLOBAL ANTIFUNGAL TREATMENT MARKET, BY END USER
10.1 OVERVIEW
10.2 HOSPITAL AND CLINICS
10.3 DERMATOLOGICAL CLINICS
10.4 OTHERS
11 GLOBAL ANTI-FUNGAL TREATMENT MARKET, BY REGION
11.1 OVERVIEW
11.2 NORTH AMERICA
11.2.1 US
11.2.2 CANADA
11.3 EUROPE
11.3.1 GERMANY
11.3.2 FRANCE
11.3.3 UK
11.3.4 ITALY
11.3.5 SPAIN
11.3.6 SWITZERLAND
11.3.7 REST OF EUROPE
11.4 ASIA-PACIFIC
11.4.1 CHINA
11.4.2 INDIA
11.4.3 JAPAN
11.4.4 SOUTH KOREA
11.4.5 AUSTRALIA
11.4.6 REST OF ASIA-PACIFIC
11.5 REST OF THE WORLD
11.5.1 MIDDLE EAST
11.5.2 AFRICA
11.5.3 LATIN AMERICA
12 COMPETITIVE LANDSCAPE
12.1 OVERVIEW
12.2 COMPETITIVE BENCHMARKING
12.3 MAJOR GROWTH STRATEGY IN THE ANTI-FUNGAL TREATMENT MARKET
12.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE ANTI-FUNGAL TREATMENT MARKET
12.5 KEY DEVELOPMENT ANALYSIS
12.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
12.6.1 PRODUCT LAUNCH/ PRODUCT APPROVAL
12.6.2 ACQUISITION
12.6.3 AGREEMENT
12.6.4 PARTNERSHIP
12.6.5 EXPANSION
12.7 MAJOR PLAYERS FINANCIAL
12.7.1 SALES (USD BILLION), 2022
12.7.2 RESEARCH & DEVELOPMENT EXPENDITURE (USD BILLION), 2022
13 COMPANY PROFILES
13.1 PFIZER INC
13.1.1 COMPANY OVERVIEW
13.1.2 FINANCIAL OVERVIEW
13.1.3 PRODUCTS OFFERED
13.1.4 KEY DEVELOPMENTS
13.1.5 SWOT ANALYSIS
13.1.6 KEY STRATEGIES
13.2 MERCK KGAA
13.2.1 COMPANY OVERVIEW
13.2.2 FINANCIAL OVERVIEW
13.2.3 PRODUCTS OFFERED
13.2.4 KEY DEVELOPMENTS
13.2.5 SWOT ANALYSIS
13.2.6 KEY STRATEGIES
13.3 GILEAD SCIENCES, INC
13.3.1 COMPANY OVERVIEWS
13.3.2 FINANCIAL OVERVIEW
13.3.3 PRODUCTS OFFERED
13.3.4 KEY DEVELOPMENTS
13.3.5 KEY STRATEGIES
13.4 BAYER AG
13.4.1 COMPANY OVERVIEW
13.4.2 FINANCIAL OVERVIEW
13.4.3 PRODUCTS OFFERED
13.4.4 KEY DEVELOPMENTS
13.4.5 KEY STRATEGIES
13.5 CIPLA INC
13.5.1 COMPANY OVERVIEW
13.5.2 FINANCIAL OVERVIEW
13.5.3 PRODUCTS OFFERED
13.5.4 KEY DEVELOPMENTS
13.5.5 KEY STRATEGIES
13.6 NOVARTIS AG
13.6.1 COMPANY OVERVIEW
13.6.2 FINANCIAL OVERVIEW
13.6.3 PRODUCTS OFFERED
13.6.4 KEY DEVELOPMENTS
13.6.5 SWOT ANALYSIS
13.6.6 KEY STRATEGIES
13.7 SANOFI S.A.
13.7.1 COMPANY OVERVIEW
13.7.2 FINANCIAL OVERVIEW
13.7.3 PRODUCTS OFFERED
13.7.4 KEY DEVELOPMENTS
13.7.5 SWOT ANALYSIS
13.7.6 KEY STRATEGIES
13.8 ABBOTT
13.8.1 COMPANY OVERVIEW
13.8.2 FINANCIAL OVERVIEW
13.8.3 PRODUCTS OFFERED
13.8.4 KEY DEVELOPMENTS
13.8.5 KEY STRATEGIES
13.9 JOHNSON & JOHNSON SERVICES, INC
13.9.1 COMPANY OVERVIEW
13.9.2 FINANCIAL OVERVIEW
13.9.3 PRODUCTS OFFERED
13.9.4 KEY DEVELOPMENTS
13.9.5 SWOT ANALYSIS
13.9.6 KEY STRATEGIES
13.10 GLAXOSMITHKLINE PLC
13.10.1 COMPANY OVERVIEW
13.10.2 FINANCIAL OVERVIEW
13.10.3 PRODUCTS OFFERED
13.10.4 KEY DEVELOPMENTS
13.10.5 KEY STRATEGIES
14 APPENDIX
14.1 REFERENCES
14.2 RELATED REPORTS
LIST OF TABLES
TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS
TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
TABLE 3 GLOBAL ANTIFUNGAL TREATMENT MARKET, BY DRUG CLASS, 2019–2032 (USD BILLION)
TABLE 4 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR AZOLES, BY REGION 2019–2032 (USD BILLION)
TABLE 5 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR ECHINOCANDINS, BY REGION 2019–2032 (USD BILLION)
TABLE 6 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR POLYENES, BY REGION 2019–2032 (USD BILLION)
TABLE 7 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR ALLYLAMINES, BY REGION 2019–2032 (USD BILLION)
TABLE 8 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR PYRIMIDINES, BY REGION 2019–2032 (USD BILLION)
TABLE 9 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR OTHERS, BY REGION 2019–2032 (USD BILLION)
TABLE 10 GLOBAL ANTIFUNGAL TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD BILLION)
TABLE 11 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR ORAL, BY REGION 2019–2032 (USD BILLION)
TABLE 12 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR TOPICAL, BY REGION 2019–2032 (USD BILLION)
TABLE 13 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR PARENTERAL, BY REGION 2019–2032(USD BILLION)
TABLE 14 GLOBAL ANTIFUNGAL TREATMENT MARKET, BY INDICATION, 2019–2032(USD BILLION)
TABLE 15 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR DERMATOPHYTOSIS, BY REGION 2019–2032 (USD BILLION)
TABLE 16 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR ASPERGILLOSIS, BY REGION 2019–2032 (USD BILLION)
TABLE 17 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR CANDIDIASIS, BY REGION 2019–2032 (USD BILLION)
TABLE 18 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR INVASIVE CANDIDIASIS, BY REGION 2019–2032 (USD BILLION)
TABLE 19 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR VULVOVAGINAL CANDIDIASIS, BY REGION 2019–2032 (USD BILLION)
TABLE 20 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR MOUTH/THROAT/ESOPHAGEAL CANDIDIASIS, BY REGION 2019–2032 (USD BILLION)
TABLE 21 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR OTHERS, BY REGION 2019–2032 (USD BILLION)
TABLE 22 GLOBAL ANTIFUNGAL TREATMENT MARKET, BY PATHOGENS, 2019–2032 (USD BILLION)
TABLE 23 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR CANDIDA, BY REGION 2019–2032 (USD BILLION)
TABLE 24 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR ASPERGILLUS, BY REGION 2019–2032 (USD BILLION)
TABLE 25 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR CRYPTOCOCCUS, BY REGION 2019–2032 (USD BILLION)
TABLE 26 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR CANDIDIASIS, BY REGION 2019–2032 (USD BILLION)
TABLE 27 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR ZYGOMYCETES, BY REGION 2019–2032 (USD BILLION)
TABLE 28 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR TRICHOPHYTON, BY REGION 2019–2032 (USD BILLION)
TABLE 29 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR OTHERS, BY REGION 2019–2032 (USD BILLION)
TABLE 30 GLOBAL ANTIFUNGAL TREATMENT MARKET, BY END USER, 2019–2032 (USD BILLION)
TABLE 31 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR HOSPITALS AND CLINICS, BY REGION 2019–2032 (USD BILLION)
TABLE 32 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR DERMATOLOGICAL CLINICS, BY REGION 2019–2032(USD BILLION)
TABLE 33 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR OTHERS, BY REGION 2019–2032 (USD BILLION)
TABLE 34 GLOBAL: ANTI-FUNGAL TREATMENT MARKET, BY REGION, 2019–2032(USD BILLION)
TABLE 35 NUMBER OF DEATHS FROM FUNGAL INFECTIONS IN THE US DURING 2019–2021
TABLE 36 NORTH AMERICA: ANTI-FUNGAL TREATMENT MARKET, BY COUNTRY, 2019–2032(USD BILLION)
TABLE 37 NORTH AMERICA: ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2019–2032(USD BILLION)
TABLE 38 NORTH AMERICA: ANTI-FUNGAL TREATMENT MARKET BY ROUTE OF ADMINISTRATION, 2019–2032(USD BILLION)
TABLE 39 NORTH AMERICA: ANTI-FUNGAL TREATMENT MARKET BY INDICATION, 2019–2032(USD BILLION)
TABLE 40 NORTH AMERICA: ANTI-FUNGAL TREATMENT MARKET BY PATHOGEN, 2019–2032(USD BILLION)
TABLE 41 NORTH AMERICA: ANTI-FUNGAL TREATMENT MARKET BY END USER, 2019–2032(USD BILLION)
TABLE 42 US: ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2019–2032(USD BILLION)
TABLE 43 US: ANTI-FUNGAL TREATMENT MARKET BY ROUTE OF ADMINISTRATION, 2019–2032(USD BILLION)
TABLE 44 US: ANTI-FUNGAL TREATMENT MARKET BY INDICATION, 2019–2032(USD BILLION)
TABLE 45 US: ANTI-FUNGAL TREATMENT MARKET BY PATHOGEN, 2019–2032(USD BILLION)
TABLE 46 US: ANTI-FUNGAL TREATMENT MARKET BY END USER, 2019–2032(USD BILLION)
TABLE 47 CANADA: ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2019–2032(USD BILLION)
TABLE 48 CANADA: ANTI-FUNGAL TREATMENT MARKET BY ROUTE OF ADMINISTRATION, 2019–2032(USD BILLION)
TABLE 49 CANADA: ANTI-FUNGAL TREATMENT MARKET BY INDICATION, 2019–2032(USD BILLION)
TABLE 50 CANADA: ANTI-FUNGAL TREATMENT MARKET BY PATHOGEN, 2019–2032(USD BILLION)
TABLE 51 CANADA: ANTI-FUNGAL TREATMENT MARKET BY END USER, 2019–2032(USD BILLION)
TABLE 52 EUROPE: ANTI-FUNGAL TREATMENT MARKET, BY COUNTRY, 2019–2032(USD BILLION)
TABLE 53 EUROPE: ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2019–2032 (USD BILLION)
TABLE 54 EUROPE: ANTI-FUNGAL TREATMENT MARKET BY ROUTE OF ADMINISTRATION, 2019–2032(USD BILLION)
TABLE 55 EUROPE: ANTI-FUNGAL TREATMENT MARKET BY INDICATION, 2019–2032(USD BILLION)
TABLE 56 EUROPE: ANTI-FUNGAL TREATMENT MARKET BY PATHOGEN, 2019–2032(USD BILLION)
TABLE 57 EUROPE: ANTI-FUNGAL TREATMENT MARKET BY END USER, 2019–2032(USD BILLION)
TABLE 58 GERMANY: ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2019–2032(USD BILLION)
TABLE 59 GERMANY: ANTI-FUNGAL TREATMENT MARKET BY ROUTE OF ADMINISTRATION, 2019–2032(USD BILLION)
TABLE 60 GERMANY: ANTI-FUNGAL TREATMENT MARKET BY INDICATION, 2019–2032(USD BILLION)
TABLE 61 GERMANY ANTI-FUNGAL TREATMENT MARKET BY PATHOGEN, 2019–2032(USD BILLION)
TABLE 62 GERMANY: ANTI-FUNGAL TREATMENT MARKET BY END USER, 2019–2032(USD BILLION)
TABLE 63 FRANCE: ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2019–2032(USD BILLION)
TABLE 64 FRANCE: ANTI-FUNGAL TREATMENT MARKET BY ROUTE OF ADMINISTRATION, 2019–2032(USD BILLION)
TABLE 65 FRANCE: ANTI-FUNGAL TREATMENT MARKET BY INDICATION, 2019–2032(USD BILLION)
TABLE 66 FRANCE: ANTI-FUNGAL TREATMENT MARKET BY PATHOGEN, 2019–2032(USD BILLION)
TABLE 67 FRANCE: ANTI-FUNGAL TREATMENT MARKET BY END USER, 2019–2032(USD BILLION)
TABLE 68 UK: ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2019–2032(USD BILLION)
TABLE 69 UK: ANTI-FUNGAL TREATMENT MARKET BY ROUTE OF ADMINISTRATION, 2019–2032(USD BILLION)
TABLE 70 UK: ANTI-FUNGAL TREATMENT MARKET BY INDICATION, 2019–2032(USD BILLION)
TABLE 71 UK: ANTI-FUNGAL TREATMENT MARKET BY PATHOGEN, 2019–2032(USD BILLION)
TABLE 72 UK: ANTI-FUNGAL TREATMENT MARKET BY END USER, 2019–2032(USD BILLION)
TABLE 73 ITALY: ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2019–2032(USD BILLION)
TABLE 74 ITALY: ANTI-FUNGAL TREATMENT MARKET BY ROUTE OF ADMINISTRATION, 2019–2032(USD BILLION)
TABLE 75 ITALY: ANTI-FUNGAL TREATMENT MARKET BY INDICATION, 2019–2032(USD BILLION)
TABLE 76 ITALY: ANTI-FUNGAL TREATMENT MARKET BY PATHOGEN, 2019–2032(USD BILLION)
TABLE 77 ITALY: ANTI-FUNGAL TREATMENT MARKET BY END USER, 2019–2032(USD BILLION)
TABLE 78 SPAIN: ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2019–2032(USD BILLION)
TABLE 79 SPAIN: ANTI-FUNGAL TREATMENT MARKET BY ROUTE OF ADMINISTRATION, 2019–2032(USD BILLION)
TABLE 80 SPAIN: ANTI-FUNGAL TREATMENT MARKET BY INDICATION, 2019–2032(USD BILLION)
TABLE 81 SPAIN: ANTI-FUNGAL TREATMENT MARKET BY PATHOGEN, 2019–2032(USD BILLION)
TABLE 82 SPAIN: ANTI-FUNGAL TREATMENT MARKET BY END USER, 2019–2032(USD BILLION)
TABLE 83 SWITZERLAND: ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2019–2032(USD BILLION)
TABLE 84 SWITZERLAND: ANTI-FUNGAL TREATMENT MARKET BY ROUTE OF ADMINISTRATION, 2019–2032(USD BILLION)
TABLE 85 SWITZERLAND: ANTI-FUNGAL TREATMENT MARKET BY INDICATION, 2019–2032(USD BILLION)
TABLE 86 SWITZERLAND: ANTI-FUNGAL TREATMENT MARKET BY PATHOGEN, 2019–2032(USD BILLION)
TABLE 87 SWITZERLAND: ANTI-FUNGAL TREATMENT MARKET BY END USER, 2019–2032(USD BILLION)
TABLE 88 REST OF EUROPE: ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2019–2032(USD BILLION)
TABLE 89 REST OF EUROPE: ANTI-FUNGAL TREATMENT MARKET BY ROUTE OF ADMINISTRATION, 2019–2032(USD BILLION)
TABLE 90 REST OF EUROPE: ANTI-FUNGAL TREATMENT MARK
